The results of the combination of epalrestat and MCC950 treatment on NASH also showed that caspase-1 p20 expression, and IL-1β and TNF-α mRNA levels in the liver tissue could be suppressed by the combination treatment and the therapeutic effect better than both administered separately (Fig. 6D–G). This evidence concerns the gene TNF and metabolic dysfunction-associated steatohepatitis.